Suppr超能文献

在人源化严重联合免疫缺陷小鼠中建立特发性肺纤维化模型。

Modeling Idiopathic Pulmonary Fibrosis in Humanized Severe Combined Immunodeficient Mice.

机构信息

Women's Guild Lung Institute, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California.

Women's Guild Lung Institute, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California.

出版信息

Am J Pathol. 2018 Apr;188(4):891-903. doi: 10.1016/j.ajpath.2017.12.020. Epub 2018 Feb 17.

Abstract

Idiopathic pulmonary fibrosis (IPF) is a fibrotic lung disease of unknown etiopathogenesis with limited therapeutic options. IPF is characterized by an abundance of fibroblasts and loss of epithelial progenitors, which cumulates in unrelenting fibrotic lung remodeling and loss of normal oxygenation. IPF has been challenging to model in rodents; nonetheless, mouse models of lung fibrosis provide clues as to the natural progression of lung injury and remodeling, but many have not been useful in predicting efficacy of therapeutics in clinical IPF. We provide a detailed methodologic description of various iterations of humanized mouse models, initiated by the i.v. injection of cells from IPF lung biopsy or explants specimens into severe combined immunodeficiency (SCID)/beige or nonobese diabetic SCID γ mice. Unlike cells from normal lung samples, IPF cells promote persistent, nonresolving lung remodeling in SCID mice. Finally, we provide examples and discuss potential advantages and pitfalls of human-specific targeting approaches in a humanized SCID model of pulmonary fibrosis.

摘要

特发性肺纤维化(IPF)是一种病因不明的肺纤维化疾病,治疗选择有限。IPF 的特征是成纤维细胞增多和上皮祖细胞丧失,导致持续不断的纤维化肺重塑和正常氧合丧失。在啮齿动物中很难对 IPF 进行建模;然而,肺纤维化的小鼠模型为肺损伤和重塑的自然进展提供了线索,但许多模型在预测临床 IPF 治疗的疗效方面并不有用。我们提供了各种人源化小鼠模型的详细方法描述,这些模型是通过将来自 IPF 肺活检或外植体标本的细胞静脉注射到严重联合免疫缺陷(SCID)/ beige 或非肥胖型糖尿病 SCID γ 小鼠中来启动的。与来自正常肺样本的细胞不同,IPF 细胞在 SCID 小鼠中促进持续的、不可解决的肺重塑。最后,我们提供了在肺纤维化的人源化 SCID 模型中使用人特异性靶向方法的示例,并讨论了其潜在的优点和陷阱。

相似文献

1
Modeling Idiopathic Pulmonary Fibrosis in Humanized Severe Combined Immunodeficient Mice.
Am J Pathol. 2018 Apr;188(4):891-903. doi: 10.1016/j.ajpath.2017.12.020. Epub 2018 Feb 17.
4
The heterodimer S100A8/A9 is a potent therapeutic target for idiopathic pulmonary fibrosis.
J Mol Med (Berl). 2021 Jan;99(1):131-145. doi: 10.1007/s00109-020-02001-x. Epub 2020 Nov 9.
5
CD148 Deficiency in Fibroblasts Promotes the Development of Pulmonary Fibrosis.
Am J Respir Crit Care Med. 2021 Aug 1;204(3):312-325. doi: 10.1164/rccm.202008-3100OC.
6
Targeting of TAM Receptors Ameliorates Fibrotic Mechanisms in Idiopathic Pulmonary Fibrosis.
Am J Respir Crit Care Med. 2018 Jun 1;197(11):1443-1456. doi: 10.1164/rccm.201707-1519OC.
8
CCR10+ epithelial cells from idiopathic pulmonary fibrosis lungs drive remodeling.
JCI Insight. 2018 Aug 23;3(16). doi: 10.1172/jci.insight.122211.
10
Lung Fibroblasts, Aging, and Idiopathic Pulmonary Fibrosis.
Ann Am Thorac Soc. 2016 Dec;13 Suppl 5:S417-S421. doi: 10.1513/AnnalsATS.201605-341AW.

引用本文的文献

2
Biomaterial-based 3D human lung models replicate pathological characteristics of early pulmonary fibrosis.
bioRxiv. 2025 Feb 17:2025.02.12.637970. doi: 10.1101/2025.02.12.637970.
4
Translational Studies Reveal the Divergent Effects of Simtuzumab Targeting LOXL2 in Idiopathic Pulmonary Fibrosis.
Fibrosis (Hong Kong). 2023 Dec;1(2). doi: 10.35534/fibrosis.2023.10007. Epub 2023 Nov 28.
6
HER2 drives lung fibrosis by activating a metastatic cancer signature in invasive lung fibroblasts.
J Exp Med. 2022 Oct 3;219(10). doi: 10.1084/jem.20220126. Epub 2022 Aug 18.
7
Lung Organoids-The Ultimate Tool to Dissect Pulmonary Diseases?
Front Cell Dev Biol. 2022 Jul 13;10:899368. doi: 10.3389/fcell.2022.899368. eCollection 2022.
8
The perplexing role of RAGE in pulmonary fibrosis: causality or casualty?
Ther Adv Respir Dis. 2021 Jan-Dec;15:17534666211016071. doi: 10.1177/17534666211016071.
9
Antibody-mediated depletion of CCR10+EphA3+ cells ameliorates fibrosis in IPF.
JCI Insight. 2021 Jun 8;6(11):141061. doi: 10.1172/jci.insight.141061.

本文引用的文献

2
IPF lung fibroblasts have a senescent phenotype.
Am J Physiol Lung Cell Mol Physiol. 2017 Dec 1;313(6):L1164-L1173. doi: 10.1152/ajplung.00220.2017. Epub 2017 Aug 31.
3
A Phase 2 Randomized Controlled Study of Tralokinumab in Subjects with Idiopathic Pulmonary Fibrosis.
Am J Respir Crit Care Med. 2018 Jan 1;197(1):94-103. doi: 10.1164/rccm.201704-0784OC.
4
Senolytic drugs target alveolar epithelial cell function and attenuate experimental lung fibrosis .
Eur Respir J. 2017 Aug 3;50(2). doi: 10.1183/13993003.02367-2016. Print 2017 Aug.
5
Predicting Life Expectancy for Pirfenidone in Idiopathic Pulmonary Fibrosis.
J Manag Care Spec Pharm. 2017 Mar;23(3-b Suppl):S17-S24. doi: 10.18553/jmcp.2017.23.3-b.s17.
6
Cellular senescence mediates fibrotic pulmonary disease.
Nat Commun. 2017 Feb 23;8:14532. doi: 10.1038/ncomms14532.
7
Microbes Are Associated with Host Innate Immune Response in Idiopathic Pulmonary Fibrosis.
Am J Respir Crit Care Med. 2017 Jul 15;196(2):208-219. doi: 10.1164/rccm.201607-1525OC.
8
Host-Microbial Interactions in Idiopathic Pulmonary Fibrosis.
Am J Respir Crit Care Med. 2017 Jun 15;195(12):1640-1650. doi: 10.1164/rccm.201607-1408OC.
9
10
Telomere dysfunction in alveolar epithelial cells causes lung remodeling and fibrosis.
JCI Insight. 2016 Sep 8;1(14):e86704. doi: 10.1172/jci.insight.86704.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验